Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 2/20 | 0.42 |
| ▸ | MAPK14 | Q16539 | 7/20 | 0.41 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.39 |
| ▸ | CFTR | P13569 | 2/20 | 0.36 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | GLA | P06280 | 1/20 | 0.35 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.35 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14323684 | 0.92 | BRD4 (0.41) | BRD4MAPK14NOTUMCYP19A1NPC1 | |
| SCHEMBL14324221 | 0.90 | BRD4 (0.40) | BRD4MAPK14NOTUMCYP19A1NPC1 | |
| SCHEMBL14323716 | 0.89 | BRD4 (0.39) | BRD4MAPK14NOTUMCYP19A1GLA | |
| SCHEMBL14322602 | 0.89 | BRD4 (0.39) | BRD4MAPK14NOTUMCYP19A1GRM2 | |
| SCHEMBL14323955 | 0.81 | HDAC8 (0.43) | NOTUMCFTRNPC1RAB9AL3MBTL1 | |
| SCHEMBL14323982 | 0.73 | ESRRA (0.42) | NPC1RAB9AGLA | |
| SCHEMBL14324226 | 0.72 | HDAC8 (0.41) | NOTUMCFTRNPC1RAB9AL3MBTL1 | |
| SCHEMBL14323422 | 0.72 | HDAC8 (0.54) | NOTUMCFTRL3MBTL1GLA | |
| SCHEMBL14324505 | 0.71 | DRD2 (0.48) | BRD4NOTUMCYP19A1NPC1RAB9A | |
| SCHEMBL14322137 | 0.71 | HDAC8 (0.40) | NOTUMNPC1L3MBTL1GLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8871728-B2 | Non-peptide macrocyclic histone deacetylese (HDAC) inhibitors and methods of making and using thereof | GEORGIA TECH RESEARCH CORPORATION (US) | 2014-10-28 | — | — | US | disclosed |
| US-20120329741-A1 | NON-PEPTIDE MACROCYCLIC HISTONE DEACETYLASE (HDAC) INHIBITORS AND METHODS OF MAKING AND USING THEREOF | GEORGIA TECH RESEARCH CORPORATION | 2012-12-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120329741-A1 | NON-PEPTIDE MACROCYCLIC HISTONE DEACETYLASE (HDAC) INHIBITORS AND METHODS OF MAKING AND USING THEREOF | HDAC5, HDAC3, HDAC1 | BRD4 219/4885MAPK14 3709/4885NOTUM 56/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.